Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.
$VKTX
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/29/2025 | $104.00 | Overweight | Cantor Fitzgerald |
| 4/8/2025 | $30.00 | Neutral | Goldman |
| 2/13/2025 | $102.00 | Sector Outperform | Scotiabank |
| 2/7/2025 | $38.00 | Neutral | Citigroup |
| 12/2/2024 | Overweight | Piper Sandler | |
| 11/22/2024 | $109.00 | Buy | B. Riley Securities |
| 11/4/2024 | $90.00 → $102.00 | Buy | H.C. Wainwright |
| 9/11/2024 | $80.00 | Overweight | JP Morgan |
Study Achieves Primary and Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight with Once-Daily VK2735 Dosing as Compared to Placebo Up to 12.2% (26.6 lbs) Mean Weight Loss Observed After 13 Weeks of VK2735 Treatment Compared with 1.3% (2.9 lbs) for Placebo Exploratory Assessment of Low Dose Maintenance Treatment Demonstrates Positive Proof of Concept VK2735 Shown to be Safe and Well-Tolerated in 13-Week Study; 99% of GI-specific Treatment Emergent Adverse Events Considered Mild or Moderate Conference Call Scheduled for 8:00 a.m. ET Today SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmac
Conference call scheduled for 4:30 p.m. ET today Phase 3 VANQUISH Registration Trials Underway for VK2735 in ObesityPhase 2 VENTURE-Oral Dosing Trial Enrollment Completed; Top-Line Results Expected 2H25Continued Progress with Amylin Program; IND Planned 4Q25Strong Quarter-End Cash Position of $808 MillionSAN DIEGO, July 23, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2025, and provided an update on its clinical pipeline and other corporate developm
Conference Call Scheduled for Wednesday, July 23 at 4:30 p.m. Eastern Time SAN DIEGO, July 16, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the second quarter 2025 after the market close on Wednesday, July 23, 2025. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, July 23, 2025. To participate on the conference call, please dial (844) 850-0543 from the U.S. or
8-K - Viking Therapeutics, Inc. (0001607678) (Filer)
SCHEDULE 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
10-Q - Viking Therapeutics, Inc. (0001607678) (Filer)
Cantor Fitzgerald initiated coverage of Viking Therapeutics with a rating of Overweight and set a new price target of $104.00
Goldman initiated coverage of Viking Therapeutics with a rating of Neutral and set a new price target of $30.00
Scotiabank initiated coverage of Viking Therapeutics with a rating of Sector Outperform and set a new price target of $102.00
Study Achieves Primary and Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight with Once-Daily VK2735 Dosing as Compared to Placebo Up to 12.2% (26.6 lbs) Mean Weight Loss Observed After 13 Weeks of VK2735 Treatment Compared with 1.3% (2.9 lbs) for Placebo Exploratory Assessment of Low Dose Maintenance Treatment Demonstrates Positive Proof of Concept VK2735 Shown to be Safe and Well-Tolerated in 13-Week Study; 99% of GI-specific Treatment Emergent Adverse Events Considered Mild or Moderate Conference Call Scheduled for 8:00 a.m. ET Today SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmac
Conference call scheduled for 4:30 p.m. ET today Phase 3 VANQUISH Registration Trials Underway for VK2735 in ObesityPhase 2 VENTURE-Oral Dosing Trial Enrollment Completed; Top-Line Results Expected 2H25Continued Progress with Amylin Program; IND Planned 4Q25Strong Quarter-End Cash Position of $808 MillionSAN DIEGO, July 23, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2025, and provided an update on its clinical pipeline and other corporate developm
Conference Call Scheduled for Wednesday, July 23 at 4:30 p.m. Eastern Time SAN DIEGO, July 16, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the second quarter 2025 after the market close on Wednesday, July 23, 2025. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, July 23, 2025. To participate on the conference call, please dial (844) 850-0543 from the U.S. or
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4/A - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)